Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health has identified an additional $10 million in annualized cost reductions, which enhances its potential for increased operational efficiency and profitability. The company's BioReference Health (BRH) division is approximately $3 million away from achieving profitability at the operating line, excluding non-recurring costs, with full implementation of cost reductions anticipated in the second half of 2025. Additionally, OPKO is expected to achieve adjusted EBITDA positivity on a forward-looking basis, partly supported by a $5.7 million depreciation and amortization expense recorded in the first quarter.

Bears say

OPKO Health Inc. has reported a disappointing earnings per share (EPS) of -$0.10 for the latest quarter, falling short of expectations by five cents, which raises concerns about its financial performance. The revenue contributions from its BARDA and NGENLA segments were underwhelming, with the latter declining significantly compared to the previous year and meeting only half of anticipated expectations. Given these factors, the negative financial trends point to potential challenges within OPKO Health’s operational efficiency and market demand for its products, leading to a cautious outlook on its stock performance.

OPKO Health (OPK) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 2 analysts, OPKO Health (OPK) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.